These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6577781)

  • 1. Influence of clofibrate, bile-sequestering agents and probucol on high-density lipoprotein levels.
    Glueck C
    Am J Cardiol; 1983 Aug; 52(4):28B-30B. PubMed ID: 6577781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
    Tomikawa M; Nakayasu T; Tawara K; Abiko Y
    Atherosclerosis; 1981 Oct; 40(2):101-13. PubMed ID: 6946776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein fractions and receptors: a role for probucol?
    Bilheimer DW
    Am J Cardiol; 1986 Jun; 57(16):7H-15H. PubMed ID: 3637051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of probucol on lipoprotein protein kinetics.
    Nestel PJ
    Artery; 1982; 10(2):95-8. PubMed ID: 7092582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibric acids: effects on lipids and lipoprotein metabolism.
    Grundy SM; Vega GL
    Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats.
    Kamanna VS; Newman HA; Patel ST; Tehim AK; Witiak DT; Feller DR
    Lipids; 1989 Jan; 24(1):25-32. PubMed ID: 2747427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action and adverse effects of lipid lowering drugs.
    Eghdamian B; Ghose K
    Drugs Today (Barc); 1998 Nov; 34(11):943-56. PubMed ID: 14743263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis.
    Nestel PJ; Billington T
    Atherosclerosis; 1981; 38(1-2):203-9. PubMed ID: 7470200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
    Atmeh RF; Stewart JM; Boag DE; Packard CJ; Lorimer AR; Shepherd J
    J Lipid Res; 1983 May; 24(5):588-95. PubMed ID: 6875383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K; Gartside PS; Hynd BA; Kashyap ML
    J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Currently available hypolipidaemic drugs and future therapeutic developments.
    Farmer JA; Gotto AM
    Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on hypoxic dyslipidaemia. Effect of lipid modulating drugs.
    Mälkönen M; Muona M; Manninen V
    Acta Med Scand Suppl; 1982; 668():130-5. PubMed ID: 6963088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical management of hyperlipidemia and the role of probucol.
    Davignon J
    Am J Cardiol; 1986 Jun; 57(16):22H-28H. PubMed ID: 3460320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
    Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
    Artery; 1993; 20(1):1-18. PubMed ID: 8447724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.